Truforma is a blood testing kit for veterinarians. It’s based on bulk acoustic wave (BAW) sensors from Qorvo (NASDAQ:QRVO). The waves are run through pet blood samples to test for adrenal and thyroid diseases.
Similarly Is Zomedica a stock to buy? ZOM stock is a risky bet in the pet diagnostics field, but it’s affordable and could provide powerful gains in the long-term. Or its downward spiral could continue; that’s a possibility which prospective investors should always consider.
What do vets say about Truforma? For its part, Zomedica says that Truforma’s feline-optimized TSH assay “will help veterinarians more readily differentiate between hyperthyroidism and euthyroid sick syndrome.” And, it states that the device’s canine eACTH assay “eliminates the risk of sample transport error and aids in the diagnosis of adrenal disease …
Additionally, Is Zomedica selling Truforma?
If ZOM management hit key milestones to capture even a small fraction of this addressable market, the company could see revenues in the millions. But so far, the company’s pride and joy, Truforma, simply isn’t selling.
What can Truforma do?
TRUFORMA is an innovative, non-optical, fluorescence-free platform that delivers accurate, reliable results when assessing complex conditions and discriminating between healthy and diseased patients.
Will Zomedica stock go up? The Zomedica Pharmaceuticals Corp stock price gained 0.26% on the last trading day (Tuesday, 12th Apr 2022), rising from $0.30 to $0.30.
…
Predicted Opening Price for Zomedica Pharmaceuticals Corp of Wednesday, April 13, 2022.
| Fair opening price April 13, 2022 | Current price |
|---|---|
| $0.30 | $0.30 (Overvalued) |
Will Zomedica recover? ZOM stock will likely struggle to recover in price over the next few months. It’s going to be awhile before this early stage company will again have the chance to prove itself to investors. Having said that, investors with a high appetite for risk, and a willingness to go against the grain, may want to buy today.
Why is Zomedica stock dropping? The reason behind the decline goes back into the previous week, when Zomedica announced its third-quarter results after the market close on Nov. 12. The veterinary health company reported revenue in the third quarter of only $22,514. It posted a net loss of $6.3 million, or $0.091 per share.
Why did Zomedica stock drop?
The reason behind the decline goes back into the previous week, when Zomedica announced its third-quarter results after the market close on Nov. 12. The veterinary health company reported revenue in the third quarter of only $22,514. It posted a net loss of $6.3 million, or $0.091 per share.
Is Truforma FDA approved? In April 2020, Zomedica announced that they had completed platform verification of TRUFORMA, which confirms the achievement of instrument design specifications, and follows FDA Medical Device design control guidelines to ensure the product was built correctly.
What’s happening to Zomedica?
Zomedica’s shares have plunged more than 80% after skyrocketing earlier this year. The company has experienced problems with a distribution partner being acquired and a development partner’s delays. Zomedica could rebound once new assays for its Truforma instrument are available.
Are vets buying Truforma? ANN ARBOR, Mich., March 16, 2021 (GLOBE NEWSWIRE) — Zomedica Corp. (NYSE American: ZOM) (“Zomedica” or the “Company”), a veterinary health company creating point-of-care diagnostics products for dogs and cats, yesterday recorded the first veterinarian sale of TRUFORMA® and officially entered commercialization.
Is Zom undervalued?
InvestorPlace’s Mark Hake estimates Zomedica (NYSEAMERICAN:ZOM) is worth between $1.11 and $1.61 a share. That makes ZOM stock a buy at current prices.
How much is Truforma cost?
Based on the revision of the average selling price of immunoassay equipment, the average selling price of TRUFORMA was adjusted up to $8,750, and the average number of units sold annually down to 1,140 units annually.
Will Zomedica go up tomorrow? Tomorrow’s movement Prediction of Zomedica Pharmaceuticals Corp ZOM as on 08 Apr 2022 appears strongly Bullish . This stock started moving upwards as soon as it opened.
…
Munafa value: 55 as on 08 Fri Apr 2022.
| Upside target | 0.33 |
|---|---|
| Upside target | 0.31 |
| Downside target | 0.3 |
| Downside target | 0.29 |
Why is Zomedica stock going up today? Shares of Zomedica ( ZOM 4.97% ) climbed on Friday after the animal health specialist struck a deal to acquire Pulse Veterinary Technologies. By the close of trading today, Zomedica’s stock price was up 9.8% after rising as much as 21.2% earlier in the day.
Why did Zomedica stock go up?
The big jump came after the veterinary health company provided a sneak peek at its 2021 fourth-quarter and full-year revenue following the market close on Friday. Zomedica reported total revenue in the fourth quarter and full-year 2021 of $4.1 million.
Why is Zomedica stock up? The big jump came after the veterinary health company provided a sneak peek at its 2021 fourth-quarter and full-year revenue following the market close on Friday. Zomedica reported total revenue in the fourth quarter and full-year 2021 of $4.1 million. The company stated that its gross margin was 73.9%.
Does Zomedica have potential?
Estimates are that this market will grow from an estimated valuation of $2.5 billion in 2021 to a projected value of $3.9 billion in 2026.
Why is Zomedica tanking? CEO Robert Cohen said the move was precipitated by « changes at our current distributor that we believe have impacted its ability to market our products effectively. » Those words likely startled investors, many of whom decided to sell their shares. Zomedica’s stock price dropped sharply on Thursday.
What is happening to Zomedica?
Zomedica’s shares have plunged more than 80% after skyrocketing earlier this year. The company has experienced problems with a distribution partner being acquired and a development partner’s delays. Zomedica could rebound once new assays for its Truforma instrument are available.